查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1588313

脊椎生物製劑市場規模、佔有率、趨勢分析報告：按產品、按手術、按最終用途、按地區、細分市場預測，2025-2030 年

Spine Biologics Market Size, Share & Trends Analysis Report By Product (Spinal Allografts, Bone Graft Substitutes, Cell-Based Matrix), By Surgery, By End Use, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

脊椎生物製劑市場成長與趨勢：

Grand View Research, Inc.最新報告顯示，到2030年，全球脊椎生物製劑市場規模預計將達到43.8億美元，2025年至2030年複合年成長率為4.9%。

這個市場主要是由脊椎損傷發生率的增加所推動的。在已開發國家和低度開發國家，脊椎畸形的盛行率都在上升，導致手術數量增加。這對脊椎生物製品市場產生了積極影響。

除此之外，人們越來越認知到生物製藥在脊椎融合手術中的許多好處，例如最大限度地縮短術後時間和激活細胞增殖的能力，也推動了市場的發展。生物材料和移植骨替代物擴大被用作脊椎畸形的治療選擇。由於患有脊椎疾病的老年人口比例不斷增加以及擴大採用這些產品作為治療方法，預計脊椎生物製劑市場在預測期內將擴大。

老年人更容易出現椎間滑脫和椎間盤退化。除此之外，道路事故和運動傷害導致的創傷病例數量不斷增加，也推動了對脊椎生物製劑的需求。根據 2018 年出版的《開放取用微創手術日誌》(MIS)，微創技術正在被用來治療多種脊椎疾病。在美國，每年約有 40 萬例手術病例，脊椎融合手術已被認為是針對脊椎創傷、退化性疾病、腫瘤和結構異常最常用和最成熟的治療方法之一。

脊椎生物製劑市場亮點

  • 脊椎植入物細分市場佔據主導地位，2024 年佔全球銷售額的 58.7%。這種優越性歸因於與使用同種異體移植物相關的許多優點。
  • 到 2024 年，醫院細分市場將佔據市場主導地位。該領域的主要驅動力是在這些設施中進行的脊椎融合手術數量不斷增加。
  • 北美佔據市場主導地位，2024 年市佔率為 48.2%。市場的成長歸因於穩定的經濟成長、微創手術的日益普及以及椎間盤相關問題、脊椎狹窄和脊椎椎間滑脫等脊椎疾病盛行率的上升。
  • 由於患者人數眾多以及患者和外科醫生對生物製藥益處的認知不斷提高，預計亞太地區的市場將出現快速成長。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章脊椎生物製劑市場變數、趨勢與範圍

  • 市場體系展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 營商環境分析
    • 產業分析-波特五力分析
    • PESTLE分析

第4章脊椎生物製品市場：產品業務分析

  • 2024年及2030年產品市場佔有率
  • 產品細分儀表板
  • 2018-2030 年按產品分類的市場規模、預測與趨勢分析
  • 同種異體脊椎移植物
  • 骨移植替代物
  • 基於細胞的矩陣

第5章脊椎生物製品市場：外科業務分析

  • 2024年及2030年手術市場佔有率
  • 手術細分儀表板
  • 2018-2030 年按手術分類的市場規模、預測與趨勢分析
  • 前路頸切除術切除融合術（ACDF）
  • 椎間腰椎椎間融合(TLIF)
  • 後側椎間融合術（PLIF）
  • 前路腰椎融合術（ALIF）
  • 側向腰椎椎間融合(LLIF)

第6章脊椎生物製品市場：最終用途業務分析

  • 2024 年及 2030 年最終用途市場佔有率
  • 最終用途細分儀表板
  • 2018-2030 年按最終用途分類的市場規模、預測與趨勢分析
  • 醫院
  • 門診設施

第7章脊椎生物製劑市場：按產品分類的區域估計和趨勢分析

  • 2024 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 2018-2030年市場規模、預測趨勢分析：
  • 北美洲
    • 按國家/地區分類，2018-2030
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 按國家/地區分類，2018-2030
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 丹麥
    • 瑞典
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 按國家/地區分類，2018-2030
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 按國家/地區分類，2018-2030
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章脊椎生物製品市場：手術區域估計和趨勢分析

  • 2024 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 2018-2030年市場規模、預測趨勢分析：
  • 北美洲
    • 按國家/地區分類，2018-2030
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 按國家/地區分類，2018-2030
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 丹麥
    • 瑞典
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 按國家/地區分類，2018-2030
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 按國家/地區分類，2018-2030
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第9章脊椎生物製劑市場：按最終用途分類的區域估計和趨勢分析

  • 2024 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 2018-2030年市場規模、預測趨勢分析：
  • 北美洲
    • 按國家/地區分類，2018-2030
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 按國家/地區分類，2018-2030
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 丹麥
    • 瑞典
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 按國家/地區分類，2018-2030
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 按國家/地區分類，2018-2030
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第10章競爭格局

  • 參與企業概況
  • 公司市場分析
  • 公司分類
  • 策略規劃
  • 公司簡介/上市公司
    • Stryker
    • NuVasive, Inc.
    • Orthofix
    • DePuy Synthes（Johnson &Johnson）
    • Exactech, Inc.
    • Zimmer Biomet
Product Code: GVR-3-68038-588-5

Spine Biologics Market Growth & Trends:

The global spine biologics market size is estimated to reach USD 4.38 billion by 2030, expanding at a CAGR of 4.9% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is primarily driven by increasing incidence of spinal injuries. Prevalence of spinal deformities has been on a rise in developed and underdeveloped countries and this has resulted in an increase in the number of surgeries being carried. This has had a positive impact on the market for spine biologics.

Apart from this, growing awareness about numerous advantages of biologics in spine fusion surgeries, such as minimal postoperative time and ability to activate cellular growth, has also propelled the market. Biomaterials and bone graft substitutes are being adopted as the choice of treatment for spinal deformities. Increasing percentage of the elderly population suffering from spinal disorders and rising adoption of these products as a treatment method is anticipated to boost the market for spine biologics over the forecast period.

The geriatric population is more prone to spondylolisthesis and degeneration of disc. This, coupled with increasing number of trauma cases due to road accidents and sports injuries, is driving demand for spine biologics. According to the Open Access Journal for Minimally Invasive Surgery (MIS) published in 2018, minimally invasive techniques are being adopted for the treatment of a wide range of spine pathologies. Approximately 400,000 cases are performed in the U.S. annually and spine fusion has turned out to be one of the most commonly performed and well-established treatment options for spine trauma, degenerative disorders, tumors, and structural abnormalities.

Spine Biologics Market Report Highlights:

  • The spinal allografts segment dominated the market and accounted for 58.7% of the global revenue in 2024. This dominance can be attributed to the numerous benefits associated with the usage of allografts.
  • The hospital segment dominated the market in 2024. The segment is primarily driven by an increased number of spine fusion surgeries performed in these facilities.
  • North America dominated the market and accounted for a 48.2% share in 2024. The growth of the market can be attributed to stable economic growth, increased adoption of minimally invasive surgeries, and rising prevalence of spine disorders such as disc-related issues, spinal stenosis, and spondylolisthesis.
  • Asia Pacific is anticipated to witness the fastest growth in the market due to the presence of a large patient pool and growing awareness among patients and surgeons about the advantages of biologics.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Surgery
    • 1.2.3. End Use
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Spine Biologics Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Spine Biologics Market: Product Business Analysis

  • 4.1. Product Market Share, 2024 & 2030
  • 4.2. Product Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Billion)
  • 4.4. Spinal Allografts
    • 4.4.1. Spinal Allografts Market, 2018 - 2030 (USD Billion)
      • 4.4.1.1. Machined Bones Allograft Market, 2018 - 2030 (USD Billion)
      • 4.4.1.2. Demineralized Bone Matrix Market, 2018 - 2030 (USD Billion)
  • 4.5. Bone Graft Substitutes
    • 4.5.1. Bone Graft Substitutes Market, 2018 - 2030 (USD Billion)
      • 4.5.1.1. Bone Morphogenetic Proteins Market, 2018 - 2030 (USD Billion)
      • 4.5.1.2. Synthetic Bone Grafts Market, 2018 - 2030 (USD Billion)
  • 4.6. Cell-based Matrix
    • 4.6.1. Cell-based Matrix Market, 2018 - 2030 (USD Billion)

Chapter 5. Spine Biologics Market: Surgery Business Analysis

  • 5.1. Surgery Market Share, 2024 & 2030
  • 5.2. Surgery Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Surgery, 2018 to 2030 (USD Billion)
  • 5.4. Anterior Cervical Discectomy and Fusion (ACDF)
    • 5.4.1. Anterior Cervical Discectomy and Fusion (ACDF) Market, 2018 - 2030 (USD Billion)
  • 5.5. Transforaminal Lumbar Interbody Fusion (TLIF)
    • 5.5.1. Transforaminal Lumbar Interbody Fusion (TLIF) Market, 2018 - 2030 (USD Billion)
  • 5.6. Posterior Lumbar Interbody Fusion (PLIF)
    • 5.6.1. Posterior Lumbar Interbody Fusion (PLIF) Market, 2018 - 2030 (USD Billion)
  • 5.7. Anterior Lumbar Interbody Fusion (ALIF)
    • 5.7.1. Anterior Lumbar Interbody Fusion (ALIF) Market, 2018 - 2030 (USD Billion)
  • 5.8. Lateral Lumbar Interbody Fusion (LLIF)
    • 5.8.1. Lateral Lumbar Interbody Fusion (LLIF) Market, 2018 - 2030 (USD Billion)

Chapter 6. Spine Biologics Market: End Use Business Analysis

  • 6.1. End Use Market Share, 2024 & 2030
  • 6.2. End Use Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Billion)
  • 6.4. Hospitals
    • 6.4.1. Hospitals Market, 2018 - 2030 (USD Billion)
  • 6.5. Outpatient Facilities
    • 6.5.1. Outpatient Facilities Market, 2018 - 2030 (USD Billion)

Chapter 7. Spine Biologics Market: Regional Estimates & Trend Analysis by Product

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.4. North America
    • 7.4.1. North America Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Regulatory Framework
      • 7.4.2.3. Competitive Insights
      • 7.4.2.4. U.S. Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Regulatory Framework
      • 7.4.3.3. Competitive Insights
      • 7.4.3.4. Canada Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Regulatory Framework
      • 7.4.4.3. Competitive Insights
      • 7.4.4.4. Mexico Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.5. Europe
    • 7.5.1. Europe Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Regulatory Framework
      • 7.5.2.3. Competitive Insights
      • 7.5.2.4. UK Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Regulatory Framework
      • 7.5.3.3. Competitive Insights
      • 7.5.3.4. Germany Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Regulatory Framework
      • 7.5.4.3. Competitive Insights
      • 7.5.4.4. France Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Regulatory Framework
      • 7.5.5.3. Competitive Insights
      • 7.5.5.4. Italy Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Regulatory Framework
      • 7.5.6.3. Competitive Insights
      • 7.5.6.4. Spain Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.7. Norway
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Regulatory Framework
      • 7.5.7.3. Competitive Insights
      • 7.5.7.4. Norway Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.8. Denmark
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Regulatory Framework
      • 7.5.8.3. Competitive Insights
      • 7.5.8.4. Denmark Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.9. Sweden
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Regulatory Framework
      • 7.5.9.3. Competitive Insights
      • 7.5.9.4. Sweden Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Regulatory Framework
      • 7.6.2.3. Competitive Insights
      • 7.6.2.4. Japan Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Regulatory Framework
      • 7.6.3.3. Competitive Insights
      • 7.6.3.4. China Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Regulatory Framework
      • 7.6.4.3. Competitive Insights
      • 7.6.4.4. India Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.5. South Korea
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Regulatory Framework
      • 7.6.5.3. Competitive Insights
      • 7.6.5.4. South Korea Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.6. Australia
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Regulatory Framework
      • 7.6.6.3. Competitive Insights
      • 7.6.6.4. Australia Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Regulatory Framework
      • 7.6.7.3. Competitive Insights
      • 7.6.7.4. Thailand Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.7. Latin America
    • 7.7.1. Latin America Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Regulatory Framework
      • 7.7.2.3. Competitive Insights
      • 7.7.2.4. Brazil Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Regulatory Framework
      • 7.7.3.3. Competitive Insights
      • 7.7.3.4. Argentina Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.8. MEA
    • 7.8.1. MEA Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Regulatory Framework
      • 7.8.2.3. Competitive Insights
      • 7.8.2.4. South Africa Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Regulatory Framework
      • 7.8.3.3. Competitive Insights
      • 7.8.3.4. Saudi Arabia Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Regulatory Framework
      • 7.8.4.3. Competitive Insights
      • 7.8.4.4. UAE Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Regulatory Framework
      • 7.8.5.3. Competitive Insights
      • 7.8.5.4. Kuwait Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 8. Spine Biologics Market: Regional Estimates & Trend Analysis by Surgery

  • 8.1. Regional Market Share Analysis, 2024 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 8.4. North America
    • 8.4.1. North America Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 8.4.2. U.S.
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Regulatory Framework
      • 8.4.2.3. Competitive Insights
      • 8.4.2.4. U.S. Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.4.3. Canada
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Regulatory Framework
      • 8.4.3.3. Competitive Insights
      • 8.4.3.4. Canada Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.4.4. Mexico
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Regulatory Framework
      • 8.4.4.3. Competitive Insights
      • 8.4.4.4. Mexico Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.5. Europe
    • 8.5.1. Europe Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 8.5.2. UK
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Regulatory Framework
      • 8.5.2.3. Competitive Insights
      • 8.5.2.4. UK Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.5.3. Germany
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Regulatory Framework
      • 8.5.3.3. Competitive Insights
      • 8.5.3.4. Germany Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.5.4. France
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Regulatory Framework
      • 8.5.4.3. Competitive Insights
      • 8.5.4.4. France Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.5.5. Italy
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Regulatory Framework
      • 8.5.5.3. Competitive Insights
      • 8.5.5.4. Italy Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.5.6. Spain
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Regulatory Framework
      • 8.5.6.3. Competitive Insights
      • 8.5.6.4. Spain Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.5.7. Norway
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Regulatory Framework
      • 8.5.7.3. Competitive Insights
      • 8.5.7.4. Norway Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.5.8. Denmark
      • 8.5.8.1. Key Country Dynamics
      • 8.5.8.2. Regulatory Framework
      • 8.5.8.3. Competitive Insights
      • 8.5.8.4. Denmark Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.5.9. Sweden
      • 8.5.9.1. Key Country Dynamics
      • 8.5.9.2. Regulatory Framework
      • 8.5.9.3. Competitive Insights
      • 8.5.9.4. Sweden Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
  • 8.6. Asia Pacific
    • 8.6.1. Asia Pacific Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.6.2. Japan
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Regulatory Framework
      • 8.6.2.3. Competitive Insights
      • 8.6.2.4. Japan Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.6.3. China
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Regulatory Framework
      • 8.6.3.3. Competitive Insights
      • 8.6.3.4. China Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.6.4. India
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Regulatory Framework
      • 8.6.4.3. Competitive Insights
      • 8.6.4.4. India Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.6.5. South Korea
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Regulatory Framework
      • 8.6.5.3. Competitive Insights
      • 8.6.5.4. South Korea Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.6.6. Australia
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Regulatory Framework
      • 8.6.6.3. Competitive Insights
      • 8.6.6.4. Australia Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.6.7. Thailand
      • 8.6.7.1. Key Country Dynamics
      • 8.6.7.2. Regulatory Framework
      • 8.6.7.3. Competitive Insights
      • 8.6.7.4. Thailand Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.7. Latin America
    • 8.7.1. Latin America Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 8.7.2. Brazil
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Regulatory Framework
      • 8.7.2.3. Competitive Insights
      • 8.7.2.4. Brazil Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.7.3. Argentina
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Regulatory Framework
      • 8.7.3.3. Competitive Insights
      • 8.7.3.4. Argentina Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.8. MEA
    • 8.8.1. MEA Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 8.8.2. South Africa
      • 8.8.2.1. Key Country Dynamics
      • 8.8.2.2. Regulatory Framework
      • 8.8.2.3. Competitive Insights
      • 8.8.2.4. South Africa Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Regulatory Framework
      • 8.8.3.3. Competitive Insights
      • 8.8.3.4. Saudi Arabia Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.8.4. UAE
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Regulatory Framework
      • 8.8.4.3. Competitive Insights
      • 8.8.4.4. UAE Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.8.5. Kuwait
      • 8.8.5.1. Key Country Dynamics
      • 8.8.5.2. Regulatory Framework
      • 8.8.5.3. Competitive Insights
      • 8.8.5.4. Kuwait Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 9. Spine Biologics Market: Regional Estimates & Trend Analysis by End Use

  • 9.1. Regional Market Share Analysis, 2024 & 2030
  • 9.2. Regional Market Dashboard
  • 9.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 9.4. North America
    • 9.4.1. North America Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 9.4.2. U.S.
      • 9.4.2.1. Key Country Dynamics
      • 9.4.2.2. Regulatory Framework
      • 9.4.2.3. Competitive Insights
      • 9.4.2.4. U.S. Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.4.3. Canada
      • 9.4.3.1. Key Country Dynamics
      • 9.4.3.2. Regulatory Framework
      • 9.4.3.3. Competitive Insights
      • 9.4.3.4. Canada Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.4.4. Mexico
      • 9.4.4.1. Key Country Dynamics
      • 9.4.4.2. Regulatory Framework
      • 9.4.4.3. Competitive Insights
      • 9.4.4.4. Mexico Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.5. Europe
    • 9.5.1. Europe Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 9.5.2. UK
      • 9.5.2.1. Key Country Dynamics
      • 9.5.2.2. Regulatory Framework
      • 9.5.2.3. Competitive Insights
      • 9.5.2.4. UK Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.5.3. Germany
      • 9.5.3.1. Key Country Dynamics
      • 9.5.3.2. Regulatory Framework
      • 9.5.3.3. Competitive Insights
      • 9.5.3.4. Germany Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.5.4. France
      • 9.5.4.1. Key Country Dynamics
      • 9.5.4.2. Regulatory Framework
      • 9.5.4.3. Competitive Insights
      • 9.5.4.4. France Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.5.5. Italy
      • 9.5.5.1. Key Country Dynamics
      • 9.5.5.2. Regulatory Framework
      • 9.5.5.3. Competitive Insights
      • 9.5.5.4. Italy Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.5.6. Spain
      • 9.5.6.1. Key Country Dynamics
      • 9.5.6.2. Regulatory Framework
      • 9.5.6.3. Competitive Insights
      • 9.5.6.4. Spain Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.5.7. Norway
      • 9.5.7.1. Key Country Dynamics
      • 9.5.7.2. Regulatory Framework
      • 9.5.7.3. Competitive Insights
      • 9.5.7.4. Norway Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.5.8. Denmark
      • 9.5.8.1. Key Country Dynamics
      • 9.5.8.2. Regulatory Framework
      • 9.5.8.3. Competitive Insights
      • 9.5.8.4. Denmark Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.5.9. Sweden
      • 9.5.9.1. Key Country Dynamics
      • 9.5.9.2. Regulatory Framework
      • 9.5.9.3. Competitive Insights
      • 9.5.9.4. Sweden Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
  • 9.6. Asia Pacific
    • 9.6.1. Asia Pacific Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.6.2. Japan
      • 9.6.2.1. Key Country Dynamics
      • 9.6.2.2. Regulatory Framework
      • 9.6.2.3. Competitive Insights
      • 9.6.2.4. Japan Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.6.3. China
      • 9.6.3.1. Key Country Dynamics
      • 9.6.3.2. Regulatory Framework
      • 9.6.3.3. Competitive Insights
      • 9.6.3.4. China Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.6.4. India
      • 9.6.4.1. Key Country Dynamics
      • 9.6.4.2. Regulatory Framework
      • 9.6.4.3. Competitive Insights
      • 9.6.4.4. India Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.6.5. South Korea
      • 9.6.5.1. Key Country Dynamics
      • 9.6.5.2. Regulatory Framework
      • 9.6.5.3. Competitive Insights
      • 9.6.5.4. South Korea Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.6.6. Australia
      • 9.6.6.1. Key Country Dynamics
      • 9.6.6.2. Regulatory Framework
      • 9.6.6.3. Competitive Insights
      • 9.6.6.4. Australia Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.6.7. Thailand
      • 9.6.7.1. Key Country Dynamics
      • 9.6.7.2. Regulatory Framework
      • 9.6.7.3. Competitive Insights
      • 9.6.7.4. Thailand Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.7. Latin America
    • 9.7.1. Latin America Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 9.7.2. Brazil
      • 9.7.2.1. Key Country Dynamics
      • 9.7.2.2. Regulatory Framework
      • 9.7.2.3. Competitive Insights
      • 9.7.2.4. Brazil Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.7.3. Argentina
      • 9.7.3.1. Key Country Dynamics
      • 9.7.3.2. Regulatory Framework
      • 9.7.3.3. Competitive Insights
      • 9.7.3.4. Argentina Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.8. MEA
    • 9.8.1. MEA Spine Biologics Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 9.8.2. South Africa
      • 9.8.2.1. Key Country Dynamics
      • 9.8.2.2. Regulatory Framework
      • 9.8.2.3. Competitive Insights
      • 9.8.2.4. South Africa Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.8.3. Saudi Arabia
      • 9.8.3.1. Key Country Dynamics
      • 9.8.3.2. Regulatory Framework
      • 9.8.3.3. Competitive Insights
      • 9.8.3.4. Saudi Arabia Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.8.4. UAE
      • 9.8.4.1. Key Country Dynamics
      • 9.8.4.2. Regulatory Framework
      • 9.8.4.3. Competitive Insights
      • 9.8.4.4. UAE Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 9.8.5. Kuwait
      • 9.8.5.1. Key Country Dynamics
      • 9.8.5.2. Regulatory Framework
      • 9.8.5.3. Competitive Insights
      • 9.8.5.4. Kuwait Spine Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 10. Competitive Landscape

  • 10.1. Participant Overview
  • 10.2. Company Market Position Analysis
  • 10.3. Company Categorization
  • 10.4. Strategy Mapping
  • 10.5. Company Profiles/Listing
    • 10.5.1. Stryker
      • 10.5.1.1. Overview
      • 10.5.1.2. Financial Performance
      • 10.5.1.3. Product Benchmarking
      • 10.5.1.4. Strategic Initiatives
    • 10.5.2. NuVasive, Inc.
      • 10.5.2.1. Overview
      • 10.5.2.2. Financial Performance
      • 10.5.2.3. Product Benchmarking
      • 10.5.2.4. Strategic Initiatives
    • 10.5.3. Orthofix
      • 10.5.3.1. Overview
      • 10.5.3.2. Financial Performance
      • 10.5.3.3. Product Benchmarking
      • 10.5.3.4. Strategic Initiatives
    • 10.5.4. DePuy Synthes (Johnson & Johnson)
      • 10.5.4.1. Overview
      • 10.5.4.2. Financial Performance
      • 10.5.4.3. Product Benchmarking
      • 10.5.4.4. Strategic Initiatives
    • 10.5.5. Exactech, Inc.
      • 10.5.5.1. Overview
      • 10.5.5.2. Financial Performance
      • 10.5.5.3. Product Benchmarking
      • 10.5.5.4. Strategic Initiatives
    • 10.5.6. Zimmer Biomet
      • 10.5.6.1. Overview
      • 10.5.6.2. Financial Performance
      • 10.5.6.3. Product Benchmarking
      • 10.5.6.4. Strategic Initiatives

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. Global spine biologics market, by region, 2018 - 2030 (USD Billion)
  • Table 4. Global spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 5. Global spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 6. Global spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 7. North America spine biologics market, by country, 2018 - 2030 (USD Billion)
  • Table 8. North America spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 9. North America spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 10. North America spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 11. U.S. spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 12. U.S. spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 13. U.S. spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 14. Canada spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 15. Canada spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 16. Canada spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 17. Mexico spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 18. Mexico spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 19. Mexico spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 20. Europe spine biologics market, by country, 2018 - 2030 (USD Billion)
  • Table 21. Europe spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 22. Europe spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 23. Europe spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 24. UK spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 25. UK spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 26. UK spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 27. Germany spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 28. Germany spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 29. Germany spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 30. France spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 31. France spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 32. France spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 33. Italy spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 34. Italy spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 35. Italy spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 36. Spain spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 37. Spain spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 38. Spain spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 39. Norway spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 40. Norway spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 41. Norway spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 42. Denmark spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 43. Denmark spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 44. Denmark spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 45. Sweden spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 46. Sweden spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 47. Sweden spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 48. Asia Pacific spine biologics market, by country, 2018 - 2030 (USD Billion)
  • Table 49. Asia Pacific spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 50. Asia Pacific spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 51. Asia Pacific spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 52. Japan spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 53. Japan spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 54. Japan spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 55. China spine biologics market, by product, 2018-2030 (USD Billion)
  • Table 56. China spine biologics market, by surgery, 2018-2030 (USD Billion)
  • Table 57. China spine biologics market, by end-use, 2018-2030 (USD Billion)
  • Table 58. India spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 59. India spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 60. India spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 61. Australia spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 62. Australia spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 63. Australia spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 64. South Korea spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 65. South Korea spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 66. South Korea spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 67. Thailand spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 68. Thailand spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 69. Thailand spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 70. Latin America spine biologics market, by country, 2018 - 2030 (USD Billion)
  • Table 71. Latin America spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 72. Latin America spine biologics market, by surgery, 2018 - 2030 (USD Billion
  • Table 73. Latin America spine biologics market, by end-use, 2018 - 2030 (USD Billion
  • Table 74. Brazil spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 75. Brazil spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 76. Brazil spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 77. Argentina spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 78. Argentina spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 79. Argentina spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 80. Middle East & Africa spine biologics market, by country, 2018 - 2030 (USD Billion)
  • Table 81. Middle East & Africa spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 82. Middle East & Africa spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 83. Middle East & Africa spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 84. South Africa spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 85. South Africa spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 86. South Africa spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 87. Saudi Arabia spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 88. Saudi Arabia spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 89. Saudi Arabia spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 90. UAE spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 91. UAE spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 92. UAE spine biologics market, by end-use, 2018 - 2030 (USD Billion)
  • Table 93. Kuwait spine biologics market, by product, 2018 - 2030 (USD Billion)
  • Table 94. Kuwait spine biologics market, by surgery, 2018 - 2030 (USD Billion)
  • Table 95. Kuwait spine biologics market, by end-use, 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 Spine biologics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Product outlook (USD Billion)
  • Fig. 10 Transportation mode outlook (USD Billion)
  • Fig. 11 Competitive landscape
  • Fig. 12 Spine biologics market dynamics
  • Fig. 13 Spine biologics market: Porter's five forces analysis
  • Fig. 14 Spine biologics market: PESTLE analysis
  • Fig. 15 Spine biologics market: Product segment dashboard
  • Fig. 16 Spine biologics market: Product market share analysis, 2024 & 2030
  • Fig. 17 Spinal allografts market, 2018 - 2030 (USD Billion)
  • Fig. 18 Bone graft substitutes market, 2018 - 2030 (USD Billion)
  • Fig. 19 Cell-based matrix market, 2018 - 2030 (USD Billion)
  • Fig. 20 Spine biologics market: Surgery segment dashboard
  • Fig. 21 Spine biologics market: Surgery market share analysis, 2024 & 2030
  • Fig. 22 Anterior cervical discectomy and fusion (ACDF) market, 2018 - 2030 (USD Billion)
  • Fig. 23 Transforaminal lumbar interbody fusion (TLIF) market, 2018 - 2030 (USD Billion)
  • Fig. 24 Posterior lumbar interbody fusion (PLIF) market, 2018 - 2030 (USD Billion)
  • Fig. 25 Anterior lumbar interbody fusion (ALIF) market, 2018 - 2030 (USD Billion)
  • Fig. 26 Lateral lumbar interbody fusion (LLIF) market, 2018 - 2030 (USD Billion)
  • Fig. 27 Spine biologics market: End use segment dashboard
  • Fig. 28 Spine biologics market: End use market share analysis, 2024 & 2030
  • Fig. 29 Hospitals market, 2018 - 2030 (USD Billion)
  • Fig. 30 Outpatient facilities market, 2018 - 2030 (USD Billion)
  • Fig. 31 Spine biologics market revenue, by region
  • Fig. 32 Regional marketplace: Key takeaways
  • Fig. 33 North America spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 34 U.S. country dynamics
  • Fig. 35 U.S. spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 36 Canada country dynamics
  • Fig. 37 Canada spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 38 Mexico country dynamics
  • Fig. 39 Mexico spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 40 Europe spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 41 UK country dynamics
  • Fig. 42 UK spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 43 Germany country dynamics
  • Fig. 44 Germany spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 45 France country dynamics
  • Fig. 46 France spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 47 Italy country dynamics
  • Fig. 48 Italy spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 49 Spain country dynamics
  • Fig. 50 Spain spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 51 Norway country dynamics
  • Fig. 52 Norway spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 53 Sweden country dynamics
  • Fig. 54 Sweden spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 55 Denmark country dynamics
  • Fig. 56 Denmark spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 57 Asia Pacific spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 58 Japan country dynamics
  • Fig. 59 Japan spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 60 China country dynamics
  • Fig. 61 China spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 62 India country dynamics
  • Fig. 63 India spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 64 Australia country dynamics
  • Fig. 65 Australia spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 66 South Korea country dynamics
  • Fig. 67 South Korea spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 68 Thailand country dynamics
  • Fig. 69 Thailand spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 70 Latin America spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 71 Brazil country dynamics
  • Fig. 72 Brazil spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 73 Argentina country dynamics
  • Fig. 74 Argentina spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 75 MEA spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 76 South Africa country dynamics
  • Fig. 77 South Africa spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 78 Saudi Arabia country dynamics
  • Fig. 79 Saudi Arabia spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 80 UAE country dynamics
  • Fig. 81 UAE spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 82 Kuwait country dynamics
  • Fig. 83 Kuwait spine biologics market, 2018 - 2030 (USD Billion)
  • Fig. 84 Company categorization
  • Fig. 85 Company market position analysis
  • Fig. 86 Strategic framework